hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06294951, orgStudyIdInfo id: IIT-2023-0225, briefTitle: fMRI for BPS: A Descriptive Study of Findings and Symptoms, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: RenJi Hospital, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to investigate the relationship between functional magnetic resonance imaging (fMRI) findings of the brain and symptom presentation in patients with bladder pain syndrome (BPS). The main questions it aims to answer are:1. To explore the distribution characteristics of fMRI imaging and possible target lesions in the patient population.2. To provide appropriate clues and evidence for etiological exploration and therapeutic targeting of BPS.Participants will undergo fMRI as well as other routine laboratory tests and queries., conditionsModule conditions: Bladder Pain Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: OTHER, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: fMRI, outcomesModule primaryOutcomes measure: fMRI findings, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Renji Hospital, Shanghai Jiao Tong University School of Medicine, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200127, country: China, contacts name: Zhebin Du, Dr., role: CONTACT, phone: +86-13512179027, email: Dzbdzb1989@163.com, contacts name: Zhebin Du, Dr., role: PRINCIPAL_INVESTIGATOR, contacts name: Yinghui Fan, Dr., role: PRINCIPAL_INVESTIGATOR, contacts name: Yingfu Jiao, Dr., role: SUB_INVESTIGATOR, contacts name: Liang Dong, Dr., role: SUB_INVESTIGATOR, contacts name: Qixiang Song, Dr., role: SUB_INVESTIGATOR, contacts name: Xinxing Du, Dr., role: SUB_INVESTIGATOR, contacts name: Yanhao Dong, Dr., role: SUB_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06294938, orgStudyIdInfo id: M.WRI-2023-INQ-2224, briefTitle: Glycemic Index of Cacao Fruit Pulp in Healthy, Human Subjects, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-09-30, primaryCompletionDateStruct date: 2023-01-24, completionDateStruct date: 2023-05-23, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Mars Wrigley, class: INDUSTRY, collaborators name: INQUIS Clinical Research, descriptionModule briefSummary: Cacao fruit pulp is a sweet and fruity carbohydrate-rich edible mucilage that is often discarded. The objective of this study is to assess the glycemic response and determine the glycemic index of cacao fruit pulp., conditionsModule conditions: Blood Sugar; High, conditions: Blood Sugar; Low, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: acute, open-labeled, randomized design, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ACTUAL, armsInterventionsModule interventions name: Cacao fruit pulp, interventions name: Dextrose, outcomesModule primaryOutcomes measure: Plasma Glucose, primaryOutcomes measure: Incremental area under the curve, primaryOutcomes measure: Peak plasma glucose, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: INQUIS Clinical Research, city: Toronto, state: Onterio, zip: M5C 2N8, country: Canada, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06294925, orgStudyIdInfo id: C5041041, secondaryIdInfos id: EFFECT-UC, type: OTHER, domain: Alias Study Number, briefTitle: A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis, acronym: EFFECT-UC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2027-04-01, completionDateStruct date: 2027-04-20, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Pfizer, class: INDUSTRY, descriptionModule briefSummary: The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis.Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment choice according to the treating physician. Additionally, patients have to be between 18 and 65 years of age and should not have taken etrasimod in the past.All patients will be prescribed etrasimod according to standard of care. Assessments will be conducted according to standard of care with the exception of health questionnaires which will be completed by the patients online on their own device.The study duration is 52 weeks with 28 days of safety follow-up. Patients will visit their treating physician as they would if they were not enrolled in the study. During the study duration, patients will be asked to complete health questionnaires on a regular basis either on their mobile phone, tablet or computer.The effects of etrasimod will be analyzed for each patient comparing to their disease activity prior to the start of etrasimod., conditionsModule conditions: Colitis, Ulcerative, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 260, type: ESTIMATED, armsInterventionsModule interventions name: Etrasimod, outcomesModule primaryOutcomes measure: Proportion of patients with symptomatic remission, primaryOutcomes measure: Proportion of patients with symptomatic remission, secondaryOutcomes measure: Proportion of patients with clinical response, secondaryOutcomes measure: Proportion of patients with clinical response., secondaryOutcomes measure: Proportion of corticosteroid-free patients with symptomatic remission, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06294912, orgStudyIdInfo id: 7602-003, secondaryIdInfos id: MK-7602-003, type: OTHER, domain: Merck, briefTitle: A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-02, primaryCompletionDateStruct date: 2025-03-10, completionDateStruct date: 2025-03-10, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Merck Sharp & Dohme LLC, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum) infection., conditionsModule conditions: Malaria, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: Plasmodium falciparum, interventions name: MK-7602, interventions name: Artemether/lumefantrine, interventions name: Primaquine, interventions name: Artesunate, interventions name: Atovaquone/proguanil, outcomesModule primaryOutcomes measure: Parasite reduction ratio (PRR48) (Parts 1 and 2), primaryOutcomes measure: Parasite Clearance Half-life (PCt1/2) (Parts 1 and 2), primaryOutcomes measure: Parasite Regrowth (Parts 1 and 2), primaryOutcomes measure: Part 1 Single dose: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of MK-7602, primaryOutcomes measure: Part 1 Single dose: Maximum Plasma Concentration (Cmax) of MK-7602, primaryOutcomes measure: Part 1 Single dose: Concentration at 24 Hours (C24) of MK-7602, primaryOutcomes measure: Part 1 Single dose: Time to Maximum Plasma Concentration (Tmax) of MK-7602, primaryOutcomes measure: Part 1 Single dose: Elimination Half-life (t1/2) of MK-7602, primaryOutcomes measure: Part 2 Multiple dose: Area Under the Curve Time 0 to End of the Dosing Interval (AUC0-tau) of MK-7602, primaryOutcomes measure: Part 2 Multiple dose: Maximum Plasma Concentration (Cmax) of MK-7602, primaryOutcomes measure: Part 2 Multiple dose: Time to Maximum Plasma Concentration (Tmax) of MK-7602, primaryOutcomes measure: Part 2 Multiple dose: Elimination Half-life (t1/2) of MK-7602, secondaryOutcomes measure: Number of Participants Who Experience an Adverse Event (AE), secondaryOutcomes measure: Number of Participants Who Discontinue Study Intervention Due to an AE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06294899, orgStudyIdInfo id: 23/222-P, briefTitle: CRP and Lung Ultrasound in Respiratory Evaluation, acronym: PLURE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-05-30, completionDateStruct date: 2028-09-01, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina, class: OTHER, descriptionModule briefSummary: Lower respiratory tract infections (LRTIs) are one of the most common reasons for consultation in Primary Care centres. Differentiating between viral and bacterial aetiologies can be challenging, leading to inappropriate antibiotic prescribing. Lung ultrasound (LUS), an imaging test that gained particular relevance since the beginning of the SARS-CoV-2 pandemic, offers several advantages over the classic chest X-ray in detecting and monitoring LRTIs, especially when pleural involvement exists.This study aims to correlate LUS findings with capillary blood C-Reactive Protein (CRP) values in patients with LRTIs, evaluating LUS as a diagnostic tool and its impact on therapeutic decisions. The descriptive observational study, conducted from January 2024 to December 2026 in Lleida, will include LRTI patients attending Primary Care centres. By validating LUS as a rapid and non-invasive diagnostic tool, unnecessary antibiotic prescriptions can be reduced, promoting LUS as a complementary test in Primary Care consultations. This will facilitate appropriate diagnosis and treatment decisions for patients with LRTIs, enhancing the overall management of respiratory infections., conditionsModule conditions: C-Reactive Protein, conditions: Ultrasonography, conditions: Primary Health Care, conditions: Lower Respiratory Tract Infection, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 202, type: ESTIMATED, armsInterventionsModule interventions name: Lung ultrasound, outcomesModule primaryOutcomes measure: Ultrasound patterns, primaryOutcomes measure: C-Reactive Protein, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06294886, orgStudyIdInfo id: Innovis RD-2401, briefTitle: Vaginal Fluid Collection for Detection of Endometrial Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Innovis LLC, class: INDUSTRY, descriptionModule briefSummary: The primary objective of this study is to obtain de-identified vaginal fluid specimens from participants with an endometrial tissue biopsy-based histopathological diagnosis of endometrial cancer (EC), endometrial hyperplasia (AEH) with atypia or endometrial intraepithelial neoplasia (EIN).The samples will be used for the purpose of research and development of a new molecular diagnostic test for the detection of EC, AEH and EIN., conditionsModule conditions: Endometrial Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Screening test to detect endometrial cancer and precancer, outcomesModule primaryOutcomes measure: Detection of endometrial cancer and precancer, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Trials365, status: RECRUITING, city: Shreveport, state: Louisiana, zip: 71118, country: United States, contacts name: Jen Cory, role: CONTACT, phone: 318-408-1198, email: j.cory@trials365.org, contacts name: Destin Black, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.52515, lon: -93.75018, hasResults: False
protocolSection identificationModule nctId: NCT06294873, orgStudyIdInfo id: Innovis RD-2301, briefTitle: Stool Sample Collection Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-20, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Innovis LLC, class: INDUSTRY, collaborators name: Exact Sciences Corporation, descriptionModule briefSummary: The primary objective of this study is to obtain de-identified stool specimens from participants with colonoscopic biopsy-based histopathologic diagnosis of colorectal cancer (CRC) and/or a ≥1 cm colorectal polyp/adenoma/mass found during pre-enrollment colonoscopy that is of sufficient size to require surgical excision or complex colonoscopic polypectomy.The samples will be used for the purpose of research and development of a new molecular diagnostic test for the detection of neoplasms of the aerodigestive tract., conditionsModule conditions: Colorectal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: A screening device for the detection of colorectal and other aerodigestive tract cancers, outcomesModule primaryOutcomes measure: Detection of colon cancer or precancer, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Associated Gastroenterology Medical Group, status: RECRUITING, city: Anaheim, state: California, zip: 92810, country: United States, contacts name: Brian Riff, MD, role: CONTACT, phone: 714-778-1300, phoneExt: 227, email: briff@agmg.com, contacts name: Brian Riff, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.83529, lon: -117.9145, locations facility: Sarkis Clinical Trials, status: RECRUITING, city: Ocala, state: Florida, zip: 34474, country: United States, contacts name: Jen Corcoran, role: CONTACT, phone: 352-363-5395, phoneExt: 272, email: merci@ehsfamily.com, contacts name: Vishnu Reddy, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.1872, lon: -82.14009, locations facility: Gastro One, status: RECRUITING, city: Cordova, state: Tennessee, zip: 38018, country: United States, contacts name: Brian Dragutsky, role: CONTACT, phone: 901-606-8924, email: brian.dragutsky@onegi.com, contacts name: Ziad Younes, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 35.15565, lon: -89.7762, hasResults: False
protocolSection identificationModule nctId: NCT06294860, orgStudyIdInfo id: 01C317, briefTitle: Biological Age in Children With GH Deficiency Undergoing Hormone Replacement Therapy, acronym: ETABIOGHD, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-19, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Istituto Auxologico Italiano, class: OTHER, descriptionModule briefSummary: The primary objective of the study is to evaluate the epigenetic age in children with GH deficiency, before and after 6 months of treatment with growth hormone replacement therapy. The secondary objective is to correlate the epigenetic age with the auxometric and biochemical parameters used in the clinical-endocrinological practice. The results of the study will be useful to set up the clinical and biochemical follow-up of the hormone replacement therapy with rhGH and to understand the biomolecular mechanisms at the base of the debated "anti" or "pro" aging action of GH, the most important anabolic hormone of the human organism., conditionsModule conditions: Growth Hormone Deficiency, conditions: Short Stature, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Measurement of biological (epigenetic) age, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 15 Years, stdAges: CHILD, contactsLocationsModule locations facility: Istituto Auxologico Italiano, status: RECRUITING, city: Milano, zip: 20145, country: Italy, contacts name: Alessandro Sartorio, role: CONTACT, phone: +390261911, phoneExt: 2426, email: sartorio@auxologico.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06294821, orgStudyIdInfo id: 00003845, briefTitle: 4AP to Delay Carpal Tunnel Release (CTR), acronym: CTR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2027-12, completionDateStruct date: 2028-07, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: John Elfar, class: OTHER, descriptionModule briefSummary: The investigators have found recent promising data supporting the use of a currently FDA approved drug, 4-aminopyridine, in the treatment of nerve injury including compression neuropathy. The purpose of this research is determine whether 4-aminopyridine can delay the need for formal surgical release in patients with known carpal tunnel syndrome who would otherwise undergo surgery., conditionsModule conditions: Compression Neuropathy, conditions: Carpal Tunnel Syndrome, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 160, type: ESTIMATED, armsInterventionsModule interventions name: 4-Aminopyridine, interventions name: Placebo, outcomesModule primaryOutcomes measure: Results of symptomatic improvement in the Boston Carpal Tunnel Syndrome Questionnaire (BCTSQ), primaryOutcomes measure: Results of symptomatic improvement in the Michigan Hand Outcomes Questionnaire (MHQ), secondaryOutcomes measure: Electrodiagnostic improvement following treatment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06294808, orgStudyIdInfo id: 2017-2601, briefTitle: Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC, statusModule overallStatus: COMPLETED, startDateStruct date: 2017-07-17, primaryCompletionDateStruct date: 2020-06-30, completionDateStruct date: 2020-06-30, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: National Cancer Centre, Singapore, class: OTHER, collaborators name: Singapore General Hospital, descriptionModule briefSummary: Clinical outcomes after surgical resection in HCC is a continuum and is clearly related to tumor burden but needs better definition. The researchers describe the use of the "metro ticket" approach to analyze surgical outcomes over the whole spectrum of anatomically resectable HCC to define overall survival including intermediate stage tumors (BCLC B). The analysis the researchers provide in this study enables the clinician to select the optimal surgical resection candidate based on robust long term survival data.In addition, study compares outcome for open surgery vs laparoscopic surgery, survival outcome for viral and non-viral HCC using Albumin-Bilirubin (ALBI) for more comprehensive study result., conditionsModule conditions: Hepatocellular Carcinoma Resectable, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1043, type: ACTUAL, outcomesModule primaryOutcomes measure: 5-year mortality., primaryOutcomes measure: Concordance of pre-operative radiological and post operative surgical specimen., primaryOutcomes measure: Agreement between TBI calculated from pre-operative imaging versus those obtained from post-surgical pathological assessment., eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Cancer Centre, Singapore, city: Singapore, zip: 168583, country: Singapore, geoPoint lat: 1.28967, lon: 103.85007, locations facility: Singapore General Hospital, city: Singapore, zip: 169608, country: Singapore, geoPoint lat: 1.28967, lon: 103.85007, hasResults: False